A study of SVG103 for people with certain brain conditions and seizures
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a drug called SVG103 (Paxalisib) in adults with brain conditions that cause hard-to-control seizures: Focal Cortical Dysplasia Type II, Tuberous Sclerosis Complex, or Hemimegalencephaly. The goal is to see if SVG103 is safe and helps reduce seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have one of these conditions: Focal Cortical Dysplasia Type II (confirmed by MRI or biopsy), Tuberous Sclerosis Complex, or Hemimegalencephaly (confirmed by MRI).
- Your seizures have not been controlled by at least 2 different seizure medicines at the right doses.
- You have had at least 8 countable seizures per month for at least 2 out of the last 3 months.
- If you are on a ketogenic or modified Atkins diet, it must stay the same during the study.
- If you have a brain-stimulation device (like VNS, RNS, or DBS), it must have been implanted for at least a year with stable settings for 3 months, and the battery must last through the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This study tests an investigational drug called AV078 for people with tuberous sclerosis complex (TSC) whose seizures are not controlled by at least two current medications. The goal is to see if AV078 can reduce seizure frequency safely, and participants continue their usual seizure medications during the trial.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This study tests a personalized, non-invasive brain stimulation method called tDCS for people with drug-resistant epilepsy that starts in one part of the brain. It aims to reduce seizures in those who cannot have surgery or have not been helped by surgery.
This trial tests a new type of brain stimulation for people with temporal lobe epilepsy whose seizures come from both sides of the brain and who haven't been helped by standard treatments. The goal is to reduce seizures by sending electrical signals to a specific area of the brain.
Hear when a new Tuberous Sclerosis Complex (TSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.